June 30 (Reuters) - AbbVie (ABBV.N), opens new tab said on Monday it would acquire privately held cell therapy developer Capstan Therapeutics in a deal worth up to $2.1 billion, expanding its product ...

AbbVie has agreed to acquire Capstan Therapeutics for up to $2.1bn, adding a “high-risk, high-reward” clinical-stage in vivo CAR-T candidate to its pipeline. Capstan is developing a new type of CAR-T ...

Capstan Medical CEO Maggie Nixon offers the latest updates on her Intuitive-backed, structural hart surgical robotics startup's efforts.

AbbVie is making a full strength play for the in vivo CAR-T market, snapping up Capstan Therapeutics for $2.1 billion to add an early-phase autoimmune drug candidate to its pipeline. Capstan is part ...

Capstan Therapeutics, a biotechnology startup developing medicines that reprogram cells inside the body, has raised another $175 million to bring its first prospect into clinical testing. The ...

SAN DIEGO & PHILADELPHIA--(BUSINESS WIRE)--Capstan Therapeutics, Inc., a biotechnology company dedicated to developing and delivering precise in vivo cell engineering to patients, launched today with ...

AbbVie (ABBV) on Monday announced that it has entered into a definitive agreement to acquire privately held clinical-stage biotechnology company Capstan Therapeutics, Inc., in a bid to boost its ...

AbbVie wasn’t part of the first wave of cell therapies developed for cancer, but it is positioning itself to contend in the next one, which is expanding to therapies made by engineering immune cells ...

SAN DIEGO--(BUSINESS WIRE)--Capstan Therapeutics, Inc. (“Capstan”), a biotechnology company dedicated to advancing in vivo reprogramming of cells through RNA delivery using targeted lipid ...